Premium
Hemodialysis as a Risk Factor for Ceftriaxone‐Associated Pseudolithiasis in Adults
Author(s) -
Ubukata Masamitsu,
Ohsawa Isao,
Suzuki Hiroki,
Asao Rin,
Nakamura Yuya,
Nishida Hirofumi,
Nakamura Masayuki,
Nitta Kosaku,
Goto Yoshikazu,
Gotoh Hiromichi
Publication year - 2020
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.13445
Subject(s) - medicine , ceftriaxone , incidence (geometry) , logistic regression , gallstones , retrospective cohort study , risk factor , cholecystectomy , cohort , surgery , gastroenterology , antibiotics , physics , optics , microbiology and biotechnology , biology
Ceftriaxone‐associated biliary pseudolithiasis is common among children; however, there are only a few reports of pseudolithiasis in adult patients on HD. This retrospective cohort study included 278 adult patients on ceftriaxone therapy from 1 February 2016 to 1 September 2018. Pseudolithiasis was defined as a new development of sludge or stones in the gallbladder within 60 days of ceftriaxone therapy. After excluding patients with preexisting gallstones and a history of cholecystectomy, 113 patients on maintenance HD, and another 98 patients were enrolled as the HD and control group, respectively. Thirteen patients developed pseudolithiasis. Its incidence was significantly higher in the HD group than that in the control group. Multivariate logistic regression analyses showed that development of pseudolithiasis was significantly associated with HD and ceftriaxone dose. Therefore, HD in patients receiving ceftriaxone therapy appears to be associated with a risk of pseudolithiasis. These findings highlight the need for careful follow‐up.